An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant)

BACKGROUND: Interleukin 6 (IL-6) inhibitors are the first-line treatment for idiopathic multicentric Castleman disease (iMCD); however, there is no established treatment for cases that are resistant to IL-6 inhibitors. Although sirolimus, a mammalian target of rapamycin inhibitor, has been suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Tomohiro, Takemori, Sachiko, Hagimori, Naoko, Morimoto, Shimpei, Sumiyoshi, Remi, Shimizu, Toshimasa, Hosogaya, Naoki, Fukushima, Chizu, Yamamoto, Hiroshi, Kawakami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738043/
https://www.ncbi.nlm.nih.gov/pubmed/33327255
http://dx.doi.org/10.1097/MD.0000000000023291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738043/
https://www.ncbi.nlm.nih.gov/pubmed/33327255
http://dx.doi.org/10.1097/MD.0000000000023291

Ejemplares similares